Comparison of the Effects of High Doses of Rosuvastatin Versus Atorvastatin on the Subpopulations of High-Density Lipoproteins

American Journal of Cardiology

Volumn 99, Issue 5, 2007, Pages 681-685

  Asztalos, Bela F ^a   Le Maulf, Florence ^b   Dallal, Gerald E ^a   Stein, Evan ^c   Jones, Peter H ^d   Horvath, Katalin V ^a   McTaggart, Fergus ^b   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Medical Research Laboratory   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-I; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TRIGLYCERIDES;

EID: 33847008267     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.117     Document Type: Article

References (16)

1. Jones P.H., Hunninghake D.B., Ferdinand K.C., Stein E.A., Gold A., Caplan R.J., Blasetto J.W., and Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 26 (2004) 1388-1399
2. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W., and STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 (2003) 152-160
3. Asztalos B.F., Roheim P.S., Milani R.L., Lefevre M., McNamara J.R., Horvath K.V., and Schaefer E.J. Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2670-2676
4. Asztalos B.F., Horvath K.V., Kajinami K., Nartsupha C., Cox C.E., Batista M., Schaefer E.J., Inazu A., and Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 45 (2004) 448-455
5. Crouse III J.R., Frohlich J., Ose L., Mercuri M., and Tobert J.A. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 83 (1999) 1476-1477
6. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
7. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164 (2002) 361-369
8. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43 (2002) 1701-1717
9. Asztalos B.F., Batista M., Horvath K.V., Cox C.E., Dallal G.E., Morse J.S., Brown G.B., and Schaefer E.J. Change in alpha-1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23 (2003) 847-852
10. Asztalos B.F., Cupples L.A., Demissie S., Horvath K.V., Cox C.E., Batista M.C., and Schaefer E.J. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24 (2004) 2181-2187
11. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.B., Robins S.J., and Schaefer E.J. Value of HDL subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
12. Guerin M., Lassel T.S., Le Goff W., Farnier M., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
13. Caslake M.J., Stewart G., Day S.P., Daly E., McTaggart F., Chapman M.J., Durrington P., Laggner P., Mackness M., Pears J., and Packard C.J. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171 (2003) 245-253
14. Asztalos B.F., de la Llera-Moya M., Dallal G.E., Horvath K.V., Schaefer E.J., and Rothblat G.H. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46 (2005) 2246-2253
15. Brousseau M.E., Diffenderfer M.R., Millar J.S., Nartsupha C., Asztalos B.F., Welty F.K., Wolfe M.L., Rudling Bjorkhem M.I., Angelin B., Mancuso J.P., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25 (2005) 1057-1064
16. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., Cosgrove P.G., Sand T.M., Wester R.T., Williams J.A., Perlman M.E., and Bamberger M.J. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497